The DOI matches its Crossref record; 179 of the 181 references it cites were found in a registry or an index.
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
Open accessAbstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1ra) are novel classes of medications for type 2 diabetes that significantly reduce cardiovascular deaths independent of their effect on hyperglycemia and are widely endorsed by clinical practice guidelines.4–11”
From Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1ra) are novel classes of medications for type 2 diabetes that significantly reduce cardiovascular deaths independent of their effect on hyperglycemia and are widely endorsed by clinical practice guidelines.4–11”
From Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study (2024) · cites this paper as [9]
In the citing paper
“Professional society guidelines now recommend GLP-1RA therapy for cardiovascular risk mitigation in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors, independent of glucose control or background antihyperglycemic therapy (other diabetes medications being used).”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [15]
In the citing paper
“Society recommendations and guidelines support the concurrent use of GLP-1RAs and SGLT2 inhibitors when needed for adequate glycemic control, but data on whether such combinations may yield incremental cardiovascular advantages are lackingthusfar.15,16,21”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Flagged first, then by citations
2 of the 181 references couldn’t be matched to a known paper.
Research works printed but not linked: 8
- Bangalore, 2011, Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials, 2799
- American College of Obstetricians and Gynecologists, 2013, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy, Obstet Gynecol, 122, 1122
- Carter, 2013, Risk of incident diabetes among patients treated with statins: population based study [published correction appears in BMJ 2013;347:f4356], f2610
- Belch, 2008, he prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease, a1840
- Bethel, 2016, Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with type 2 diabetes, 224
- U.S. Food and Drug Administration, 2008, Guidance for industry. Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes
- Rosenstock, 2019, Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial, 69
- Rosenstock, 2018, Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk, 39
Cited by
Sorted by citations
Items 301–400 of 487
Gupta, U. C., Gupta, S. C., & Gupta, S. S. (2023) · Recent Advances in Food Nutrition & Agriculture · doi:10.2174/2772574x14666230725094910 · Cited by 5
Huang, R., Kong, X., Geng, R., Wu, J., Li, J., Gu, Y., Wu, Y., You, D., Zhao, Y., Ni, S., et al. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101554 · Cited by 5
Kloecker, D. E., Davies, M. J., Khunti, K., & Zaccardi, F. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14384 · Cited by 5
Wijkman, M. O., Claggett, B. L., Pfeffer, M. A., Paré, G., McQueen, M., Hess, S., Lee, S. F., & Gerstein, H. C. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107928 · Cited by 5
Tu, C., Sue, S.-P., Hsu, W., Huang, H., Wen, W., Lin, I., Chen, K., Sheu, N., Huang, S.-H., & Lee, M. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14491 · Cited by 5
Screening for primary aldosteronism in the diabetic population: a cohort study
Tan, S. J., Libianto, R., Yang, J., & Wong, J. (2022) · Internal Medicine Journal · doi:10.1111/imj.15690 · Cited by 5
The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice
Martens, P., Mathieu, C., & Vanassche, T. (2022) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2022.2076307 · Cited by 5
Xu, Z., Arnold, M., Sun, L., Stevens, D., Chung, R., Ip, S., Barrett, J., Kaptoge, S. K., Pennells, L. A. M., Angelantonio, E. D., et al. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac140 · Cited by 5
Baidya, A. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0039 · Cited by 5
Wen, W., Li, Q., She, J., Bai, X., Zhang, L., Li, R., Wu, Y., Zhou, J., & Yuan, Z. (2024) · Scientific Reports · doi:10.1038/s41598-023-50304-z · Cited by 5
Chang, L.-H., Hwu, C., Lin, Y., Huang, C., Won, J. G. S., Chen, H.-S., & Lin, L. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0114 · Cited by 5
Nwosu, B. U. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1462249 · Cited by 4
Sabbour, H. M., Bhatt, D. L., Elhenawi, Y., Aljaberi, A. K., Bennani, L., Fiad, T. M., Hasan, K. Y., Hashmani, S., Hijazi, R. A., Khan, Z., et al. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07519-z · Cited by 4
The Evolving Role of Omega 3 Fatty Acids in Cardiovascular Disease: Is Icosapent Ethyl the Answer?
Lakshmanan, S., & Budoff, M. J. (2021) · Heart International · doi:10.17925/hi.2021.15.1.7 · Cited by 4
Lu, X., Zhang, L., Li, S., He, D., Huang, T., Lin, H., Yin, H., & Lyu, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.976656 · Cited by 4
Langaas, H. C., Salvesen, Ø. O., Dyrkorn, R., Blix, H. S., & Spigset, O. (2023) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813432.2023.2222781 · Cited by 4
Lin, C., Li, C., Liu, C.-S., Lin, C., Yang, S.-Y., & Lin, C. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02243-y · Cited by 4
Cardiovascular Risk Calculators and their Applicability to South Asians
Bansal, M., Ranjan, S., & Kasliwal, R. R. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816999201001204020 · Cited by 5
Rashad, N. M., Sherif, M. H., El‐Shal, A. S., & Abdelsamad, M. A. E. (2021) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-021-00165-w · Cited by 4
Lyu, F., Cai, X., Lin, C., Hong, T., Zhang, X., Lu, J., Guo, X., Wang, Z., Xing, H., Zong, G., et al. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001741 · Cited by 6
López, L. V., Ponce-Martínez, X., Colin-Ramírez, E., Muñoz-Torres, A. V., & Escobedo, J. (2021) · Nutrición Hospitalaria · doi:10.20960/nh.03651 · Cited by 5
Hejjaji, V., Martínez, J. J. G., Tang, F., Garnelo, J. B., Cooper, A., Medina, J., Mutiozabal, M. S., Khunti, K., Nicolucci, A., Shestakova, M. V., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14745 · Cited by 4
Kuo, S., Yang, C.-T., Herman, W. H., Lisabeth, L. D., & Ye, W. (2022) · Diabetes Care · doi:10.2337/dc21-2283 · Cited by 4
Srinivasan, S., Wu, P., Mercader, J. M., Udler, M. S., Porneala, B., Bartz, T. M., Floyd, J. S., Sitlani, C. M., Guo, X., Haessler, J., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad123 · Cited by 4
Potential Role of GLP-1 Based Therapeutics in Coronary Artery Disease
Xiong, Q., Wang, J., Huang, K., Li, W., & Zhang, L. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2811315 · Cited by 4
Seuring, T., Serneels, P., Suhrcke, M., & Bachmann, M. (2020) · Economics and Human Biology · doi:10.1016/j.ehb.2020.100925 · Cited by 5
Risk Models and Scores of Cardiovascular Disease in Patients with Diabetes Mellitus
Kostopoulos, G., Antza, C., Doundoulakis, I., & Toulis, K. A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201210112743 · Cited by 4
Maarouf, O. H. (2021) · Springer eBooks · doi:10.1007/978-3-030-83082-3_6 · Cited by 6
Primary Prevention of Cardiovascular Disease Guidelines
Sajja, A. P., Alfaddagh, A., & Blumenthal, R. S. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_26 · Cited by 4
Is Heart Failure Still the Frequent, Forgotten, and Often Fatal Complication of Diabetes?
Alexander, C. M. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.01.017 · Cited by 4
Wu, H., Fang, X., Jin, D., Miao, R., Wei, J., Zhao, T., Dai, D., Liao, J., Wang, J., Lian, F., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.827697 · Cited by 3
Arenas-León, J. L., Morales-Villegas, E., Cardona-Muñóz, E. G., Alcocer-Gamba, M. A., Ramirez-Contreras, J. P., Contreras-Sandoval, A. Y., & González-Gálvez, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01231-6 · Cited by 4
Elian, V., Dorita, A., Stegaru, D., & Vinereanu, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178558 · Cited by 4
Hitting the Sweet Spot: A Review of SGLT2i in Cardiovascular Medicine
Zayyad, Z. A., Gupta, N., Roy, A., Kalagara, S., Mishra, A., Salem, E., Seshadri, S. R., Gichi, D., Hammad, B., Ene, A., et al. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00436-2 · Cited by 4
Chai, J.-T., Sun, Z., & Xu, J.-C. (2022) · Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy · doi:10.2147/dmso.s357007 · Cited by 3
Chen, X., Shi, J., Hu, Y., Ma, H., Jiang, Z., & Lou, B. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-024-01355-z · Cited by 3
Complicaciones macrovasculares de la diabetes
Costo-Muriel, C., Carmona, J. M., & Perez-Belmonte, L. M. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.011 · Cited by 5
de Kreutzenberg, S. V. (2021) · Exploration of Medicine · doi:10.37349/emed.2021.00029 · Cited by 3
Marcon, D., Tagetti, A., Piona, C. A., Giontella, A., Bortolotti, S., Bonafini, S., Carletti, L., Morandi, A., Trombetta, M., Maffeis, C., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003281 · Cited by 3
Rajput, R., Sinha, B., Lodha, S., Deb, P., Das, S., Agarwal, S., Das, A. K., & Thomas, N. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0026 · Cited by 4
Surawit, A., Pongkunakorn, T., Manosan, T., Mongkolsucharitkul, P., Chamnan, P., Suvarnabhumi, K., Puangpet, T., Suta, S., Pumeiam, S., Pinsawas, B., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-079415 · Cited by 5
Tomomatsu, Y., Takasawa, E., Iizuka, Y., Mieda, T., Inoue, H., Kimura, A., Takeshita, K., Sonoda, H., Takakura, K., Sorimachi, Y., et al. (2025) · European Spine Journal · doi:10.1007/s00586-025-08673-8 · Cited by 3
The role of icosapent ethyl in cardiovascular risk reduction
Goldenberg, R., CHENG, A. Y. Y., Gilbert, J. D., Lonn, E., Pedersen, S. D., & Verma, S. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000873 · Cited by 3
Krogh, J., Hjorthøj, C. R., Kristensen, S. L., Selmer, C., & Haugaard, S. B. (2021) · Diabetic Medicine · doi:10.1111/dme.14600 · Cited by 3
López, L. V., del Prado, P. S. C., Colin-Ramírez, E., Muñoz-Torres, A. V., & la Peña, J. E.-D. (2022) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2022.03.002 · Cited by 4
Checklist para pacientes con diabetes mellitus tipo 2 en consulta telemática
Angullo-Martínez, E., Carretero-Anibarro, E., Barrancos, I. M. S., Cos, X., Orozco‐Beltrán, D., Baile, J. L. T., Loiola, P. E., Guisasola, F. Á., Blanco, F. J. A., Lachica, L. Á., et al. (2021) · Atención Primaria · doi:10.1016/j.aprim.2021.101983 · Cited by 3
Quality of Life Assessment with EQ-5D-3L in a Moroccan Diabetic Population
Kehailou, F. Z., Jabari, M., Labriji, A., Elkhair, M. M., Bouzoubaa, H., Ouasmyne, G., Moukhtari, O. E., Amrani, S. E., & Mestaghanmi, H. (2021) · OALib · doi:10.4236/oalib.1107357 · Cited by 3
Seino, H., Onishi, Y., Eguchi, K., Nishijima, K., Sato, T., & Shirabe, S. (2023) · Diabetology International · doi:10.1007/s13340-022-00612-y · Cited by 3
Contreras, G. N., Lu, L., Tamariz, L. J., Rocco, M. V., Papademetriou, V., Kostis, J. B., Pisoni, R., Glasser, S. P., Sweeney, M. E., Basile, J., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002437 · Cited by 3
Clinical Approach to Assessment and Amelioration of Atherosclerotic Vascular Disease in Diabetes
Goldberg, R. B. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.582826 · Cited by 3
Clinical studies on pharmacological treatment of hypertension in Japan
Kario, K., Hoshide, S., Yamamoto, K. I., Okura, A., & Rakugi, H. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-021-00533-4 · Cited by 3
Bilous, F. R., Donnelly, R., & DM, F. I. I. (2021) · Wiley eBooks · doi:10.1002/9781118976074.ch19 · Cited by 3
Matthews, D. R. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14014 · Cited by 3
Biomarkers and Precision Medicine in Diabetes
Tye, S. C., Provenzano, M., & Heerspink, H. J. L. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch30 · Cited by 3
Therapeutic options and prognostic risk factors in diabetic foot osteomyelitis: a narrative review
Liu, Z., Huang, M., Ding, M.-C., Ma, X.-P., & Jiang, N. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003917 · Cited by 2
Guthrie, R. M. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1742524 · Cited by 4
Walch, A., Cobb, C. E., Tsaih, S., & Cabrera, S. M. (2020) · International Journal of Pediatric Endocrinology · doi:10.1186/s13633-020-00080-8 · Cited by 3
Cardiovascular disease risk in Hispanic American women
Hu, J., Amirehsani, K. A., McCoy, T. P., Coley, S. L., & Wallace, D. C. (2021) · Women & Health · doi:10.1080/03630242.2021.1917476 · Cited by 2
HIV in Primary Care: Case Study of Common Chronic Comorbidities
Wilkinson, M. R., Biernacki, P. J., & Knestrick, J. (2022) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2021.12.027 · Cited by 2
Toschi, E., Leblanc, J., Hafida, S., Mehta, S. N., Ritholz, M. D., Gabbay, R. A., & Laffel, L. M. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.830183 · Cited by 2
Hubbard, D. M., McKinley, E., Colantonio, L. D., Poudel, B., Rosenson, R. S., Brown, T. M., Jackson, E. A., Huang, L., Orroth, K. K., Mues, K. E., et al. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100121 · Cited by 2
Adherence to European guidelines for the use of aspirin in primary health care
Moita, C. F., Marau, G., Corte-Real, S., & Dantas, A. (2023) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2022.03.007 · Cited by 2
Chen, J., Fan, L., Maughn, K., Rey, G. G., Liu, Y., Nelson, D. R., & Hood, R. C. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15022 · Cited by 2
Zhang, D., Gao, H., Song, X., Raposeiras‐Roubín, S., Abu‐Assi, E., Henriques, J. P. S., D’Ascenzo, F., Saucedo, J., González‐Juanatey, J. R., Wilton, S. B., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110833 · Cited by 2
Scheen, A. J. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.04.014 · Cited by 2
Neto, F. L., Mendes, T. B., de Matos, P. M. P. G., de Oliveira, J. C., Favarato, M. H. S., Lin, C. A., & Martins, M. A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14303 · Cited by 1
Bonet, G., Carrasquer, A., Peiró, Ó. M., Sánchez-Giménez, R., Lal-Trehan, N., Del-Moral-Ronda, V., Fort-Gallifa, I., & Bardajı́, A. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02220-1 · Cited by 2
Taouktsi, N., Papageorgiou, S. Τ., Tousinas, G., Papanikolopoulou, S., Grammatikopoulou, M. G., Giannakoulas, G. A., & Goulis, D. G. (2022) · HORMONES · doi:10.1007/s42000-022-00396-5 · Cited by 2
Sciannameo, V., Fadini, G. P., Bottigliengo, D., Avogaro, A., Baldi, I., Gregori, D., & Berchialla, P. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192214825 · Cited by 2
Barengolts, E. I., Salim, M., Akbar, A., & Salim, F. (2020) · Nutrition and Dietary Supplements · doi:10.2147/nds.s243097 · Cited by 2
Harris, K., Muntner, P., Woodward, M., Jun, M., Oshima, M., Gong, J., Harrap, S. B., Ménard, J., & Chalmers, J. P. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-022-00661-5 · Cited by 2
Qiao, T., Zhao, H., Luo, T., Wang, D., Mu, K., Aimudula, A., Pei, H., Zhang, G., & Dai, J. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/2802828 · Cited by 2
RetractedÇelik, A., Esin, F. K., Emren, S. V., Kırış, T., & Karaca, M. (2022) · Angiology · doi:10.1177/00033197221127073 · Cited by 2
Peták, F., Kovács, B. N., Agócs, S., Virág, K., Nyári, T., Molnár, A., Südy, R., Lengyel, C., & Babik, B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274105 · Cited by 2
Treatment of Patients Chronic Coronary Heart Disease and Type 2 Diabetes Mellitus
Shchukina, E. V. S., Приколота, О. А., Bagriy, V. A., Андрусяк, А. Ю., Gs, R., Shesterina, Y. B., & Stefano, E. (2023) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2023-13-2-97-109 · Cited by 2
Willingness for Medical Screening in a Dental Setting—A Pilot Questionnaire Study
Özcan, A., Nijland, N., Gerdes, V. E. A., Bruers, J. J. M., & Loos, B. G. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20216969 · Cited by 3
Idramsyah, I., Putri, B. S. D., & Annisa, R. (2023) · Jurnal Keperawatan Silampari · doi:10.31539/jks.v7i1.6528 · Cited by 2
Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes
Arnold, S. V., GOSCH, K. L., Wong, N. D., Hejjaji, V., Goyal, A., Leiter, L. A., & Kosiborod, M. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.126 · Cited by 1
Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It?
Sarafidis, P. A., & Bakris, G. L. (2020) · Diabetes Care · doi:10.2337/dci20-0019 · Cited by 2
Glucose-Lowering Medications and Cardiovascular Outcomes
Shanmugasundaram, M., Pineda, J. R. E., & Murugapandian, S. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01452-z · Cited by 2
It Is Time to Reconsider the Blood Pressure Targets in Patients With Type 2 Diabetes?
Verdecchia, P., Reboldi, G., & Angeli, F. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21461 · Cited by 2
Bhattacharya, N., & Kumar, P. (2024) · Research Square · doi:10.21203/rs.3.rs-4310669/v1 · Cited by 2
Macro- and Microvascular Complications of Diabetes
Yang, W. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_3 · Cited by 1
Tanveer, Y., Sanipini, S., Khleif, R., Tsenteradze, T., Gapizov, A., Grezenko, H., Affaf, M., Abdelaziz, A., Rehman, A., Zia, U., et al. (2023) · Cureus · doi:10.7759/cureus.46998 · Cited by 1
Burney, S. (2023) · Isra Medical Journal · doi:10.55282/imj.oa1392 · Cited by 1
Demographic Predictors of Elevated LDL Cholesterol in Type 1 Diabetes: A Cross-Sectional Study
Dart, M. E., Patrie, J. T., & Love, K. M. (2024) · Clinical Diabetes · doi:10.2337/cd24-0051 · Cited by 1
Serdiuk, A. V., & Mogilevskyy, S. Y. (2025) · Archive of Ukrainian Ophthalmology · doi:10.22141/2309-8147.12.3.2024.388 · Cited by 1
Ranasinghe, M. P., Ranasinghe, M., Balachandran, M., Goel, V., Subasinghe, S., & Nanayakkara, S. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.09.008 · Cited by 2
Yen, F., Wei, J. C., Hung, Y., Liu, J., Hwu, C., & Hsu, C. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113267 · Cited by 1
Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity
Newman, C. B., Saunders, K. H., & Subramanian, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816569-0.00009-7 · Cited by 1
Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes
Malik, M. E., Andersson, C., Blanche, P., D’Souza, M., Madelaire, C., Zareini, B., Lamberts, M., Kristensen, S. L., Sattar, N. A., McMurray, J. J. V., et al. (2022) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02016-z · Cited by 2
HIPERTENSÃO E DIABETES: CONCEITOS ATUAIS NA TERAPÊUTICA
Faculdade de Medicina de São José do Rio Preto (FAMERP), S., Cosenso‐Martin, L. N., Yugar‐Toledo, J. C., Faculdade de Medicina de São José do Rio Preto (FAMERP), S., Vilela-Martin, J. F., & Faculdade de Medicina de São José do Rio Preto (FAMERP), S. (2021) · Revista Brasileira de Hipertensão · doi:10.47870/1519-7522/20212803213-18 · Cited by 3
Li, Y., Xie, J., Lu, B., Sun, X., Chen, F., Tong, Z., Sai, W.-W., Zhang, W., Wang, Z., & Zhong, M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.911358 · Cited by 1
Ramos‐Niño, M. E., MacLean, C. D., & Littenberg, B. (2023) · doi:10.46439/pulmonology.1.002 · Cited by 1
Blood Pressure Thresholds for Initiation of Drug Treatment: Blood Pressure Targets in Diabetes
Dhaybi, O. A., & Bakris, G. L. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_23 · Cited by 1
Qiu, W., Cai, A., Xiao, X., Gao, Z., Feng, Y., & Li, L. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01046-5 · Cited by 1
Factors Associated With the Cardiovascular Health of Black and Latino Adults With Type 2 Diabetes
McCarthy, M. M., Fletcher, J., Wright, F., Giudice, I. M. D., Wong, A., Aouizerat, B. E., Dickson, V. V., & Melkus, G. D. (2024) · Biological Research For Nursing · doi:10.1177/10998004241238237 · Cited by 1
Teixeira, L. F., Bidu, N. S., da Silva, A. L. M., da Conceição, G. C., Brustolim, D., Aras, R., & Couto, R. D. (2024) · The Open Biomarkers Journal · doi:10.2174/0118753183290270240319075030 · Cited by 1
Bhosle, D. S., Chandekar, B., & Shelke, S. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.0925 · Cited by 1
Jimeno, C., Anonuevo-Cruz, M. C., Uy, A. B., Bacena, A. O., Francisco, M. D., Tiglao-Gica, A. L., Bruno, R., & Corpuz, D. G. S. (2020) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.035.01.05 · Cited by 1
Metadata
- Authors
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-16
- Volume
- 43
- Issue
- Supplement_1
- Pages
- S111-S134
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4254135372
- Cited by
- 487
- References
- 181
- Citations by year
- 2026: 5 · 2025: 20 · 2024: 44 · 2023: 61 · 2022: 89 · 2021: 137 · 2020: 131
- FWCI
- 72.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- cardiovascular disease, cardiovascular risk management, diabetes mellitus, clinical guidelines, quality of care
- MeSH terms
- Heart Disease Risk Factors, Cardiovascular Diseases, Diabetes Mellitus, Diabetic Angiopathies, Endocrinology, Humans, Reference Standards, Societies, Medical, United States, History, 21st Century, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
